UBS Group’s RayzeBio, Inc. Common Stock RYZB Stock Holding History

UBS Group’s Portfolio RYZB Stock Details RYZB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-94,059	Closed	-$5.85M	–	10354
2023 Q4	$5.85M	Buy	94,059 +90,650	+2,659%	+$2.25M	﹤0.01%	2634
2023 Q3	$75.7K	Buy	+3,409	New	+$71.6K	﹤0.01%	6026

UBS Group's RYZB Position: Q1 2024 in Review

UBS Group sold out of RayzeBio, Inc. Common Stock (RYZB) in Q1 2024, closing a stake of 94,059 shares — an estimated $5.85M sold.

UBS Group first reported a position in RYZB in Q3 2023 and held it in 2 quarters. The position peaked at $5.85M in Q4 2023. 0 funds tracked by Wall St. Rank hold RYZB as of Q1 2024.

UBS Group reported no remaining RayzeBio, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
UBS Group sold 94,059 RayzeBio, Inc. Common Stock shares in Q1 2024, an estimated $5.85M.
UBS Group first reported a position in RayzeBio, Inc. Common Stock in Q3 2023 and held it in 2 quarters.
UBS Group's RayzeBio, Inc. Common Stock position peaked at $5.85M in Q4 2023.
0 funds tracked by Wall St. Rank held RayzeBio, Inc. Common Stock as of Q1 2024.

Based on UBS Group's 13F filing for Q1 2024, filed 13 May 2024.